Abstract
Corrigendum to Bent et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol (doi: 10.1093/neuonc/noz222) first published online November 20, 2019. In table 2, the rows in the hematology and investigation sections were misplaced one line. This has been corrected.
Cite
CITATION STYLE
Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J. S., … Golfinopoulos, V. (2021, August 1). Erratum: INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma (Neuro-Oncology DOI: 10.1093/neuonc/noz222). Neuro-Oncology. Oxford University Press. https://doi.org/10.1093/neuonc/noaa115
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
